TY - JOUR
T1 - Ending TB means responding to socially produced vulnerabilities of all genders
AU - Ringwald, Beate
AU - Mwiine, Amon Ashaba
AU - Chikovore, Jeremiah
AU - Makanda, Goodman
AU - Amoah-Larbi, Jerry
AU - Millington, Kerry
AU - Horton, Katherine C.
PY - 2023/12/9
Y1 - 2023/12/9
N2 - Globally and in Africa, tuberculosis (TB) affects more men than women, as masculine norms, behaviours, and practices can increase likelihood of exposure to TB whilst undermining engagement in TB care (1). The WHO Africa region remains particularly affected, accounting for nearly a quarter (23%) of the estimated 10.6 million people who developed TB and close to a third (31%) of the 1.6 million people who died from the disease in 2021 (2), despite being home to only 15% of the world’s population (3). 25 African countries are considered high burden countries for TB, HIV-associated TB, and drug-resistant TB (2). TB affects close to 6 million men globally and 1.3 million men in the WHO Africa region every year (2), undermining their physical health, mental well-being, and capacity to contribute to their families and communities.
AB - Globally and in Africa, tuberculosis (TB) affects more men than women, as masculine norms, behaviours, and practices can increase likelihood of exposure to TB whilst undermining engagement in TB care (1). The WHO Africa region remains particularly affected, accounting for nearly a quarter (23%) of the estimated 10.6 million people who developed TB and close to a third (31%) of the 1.6 million people who died from the disease in 2021 (2), despite being home to only 15% of the world’s population (3). 25 African countries are considered high burden countries for TB, HIV-associated TB, and drug-resistant TB (2). TB affects close to 6 million men globally and 1.3 million men in the WHO Africa region every year (2), undermining their physical health, mental well-being, and capacity to contribute to their families and communities.
U2 - 10.1136/bmjgh-2023-014151
DO - 10.1136/bmjgh-2023-014151
M3 - Comment/debate
VL - 8
SP - e014151
JO - BMJ Global Health
JF - BMJ Global Health
IS - 12
M1 - e014151
ER -